No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 1/2
Study type
Interventional
Purpose
Treatment
Participants needed
150 (estimated)
Sponsor
Repertoire Immune Medicines · Industry
Who this trial is looking for
This trial is looking for adults with advanced solid tumors that cannot be cured. Participants will receive a treatment called RPTR-1-201, either alone or combined with another medication, and help researchers understand its safety and initial effectiveness.
Are You a Good Fit for This Trial?
You may be able to join if
I have advanced solid tumors that cannot be treated for a cure.
I have at least one measurable tumor.
My performance status is 0 or 1.
My organs are functioning well.
I can provide written consent and follow trial procedures.
You may not be able to join if
I have had another cancer in the past 3 years, except for certain skin cancers.
I have active leptomeningeal disease or uncontrolled brain metastases.
I have autoimmune diseases needing immunosuppressive treatment.
I have had an organ transplant.
I have a significant medical or mental health condition that affects my safety.
Other specific reasons apply.
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
This is an early phase trial designed to evaluate the safety, tolerability, and preliminary antitumor activity of RPTR-1-201 in adults with advanced solid tumors. The trial includes dose escalation and dose expansion parts and will evaluate RPTR-1-201 as monotherapy and in combination with an anti-PD-1 monoclonal antibody.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria
* Histologically or cytologically confirmed locally advanced or metastatic solid tumors that is not amenable to curative treatment.
* At least one measurable lesion per RECIST v1.1 as assessed by the investigator.
* Eastern Cooperative Oncology Group (ECOG) performance status of …
Inclusion Criteria
* Histologically or cytologically confirmed locally advanced or metastatic solid tumors that is not amenable to curative treatment.
* At least one measurable lesion per RECIST v1.1 as assessed by the investigator.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Adequate organ function as defined in the trial protocol.
* Ability to provide written informed consent and comply with trial procedures.
Exclusion Criteria:
* History of another malignancy within 3 years before the first dose of trial intervention, with the exception of malignancies considered cured and not expected to require active therapy (for example, certain skin cancers or in situ malignancies) per protocol.
* Known active leptomeningeal disease or uncontrolled central nervous system metastases.
* Active, clinically significant, autoimmune diseases requiring systemic immunosuppressive therapy.
* Prior allogenic organ transplantation
* Clinically significant uncontrolled medical or psychiatric condition, that in the opinion of the investigator, would increase risk or interfere with trial participation.
* Other protocol-defined inclusion and exclusion criteria apply
Contacts
No contact information available.
What are you hoping to find?
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.
